#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Insulinoma Hypochondroplasia Gaucher's disease type I Herpes simplex Interstitial lung disease Pulmonary alveolar haemorrhage Duchenne muscular dystrophy gene carrier PIK3CA related overgrowth spectrum Pulmonary hypertension Colorectal adenocarcinoma Myxoid liposarcoma Follicle centre lymphoma follicular grade I II – III refractory Gastric cancer B-cell lymphoma recurrent Encephalitis autoimmune More trials…

    Learn about Rare Diseases

    Marginal zone lymphoma refractory Thrombotic thrombocytopenic purpura Hyperoxaluria – Trials in Disease Gaucher’s disease type III – Trials in Disease Ewing’s sarcoma Antithrombin III deficiency – Diagnostics Gaucher’s disease type I – Life with Disease Arterial tortuosity syndrome – Diagnostics Mucous membrane pemphigoid Primary hyperoxaluria More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Midazolam Codeine Phosphate Vafidemstat Casirivimab Tucatinib Azd5004 Tipiracil Hydrochloride Farletuzumab Ecteribulin Ads-011 Sargramostim Modafinil Caffeine Pitolisant FIBRIN Leuprorelin Acetate Ds-2325A Zalunfiban Monalizumab Dexketoprofen Deferoxamine Mesilate More therapies…

    Learn about Your Condition

    Exudative retinopathy Endometrial stromal sarcoma Pancreatitis relapsing Renal disorder Carpal tunnel syndrome Escherichia infection Glaucoma Immunosuppression Congenital aplastic anaemia Appendicitis perforated Varices oesophageal Affective disorder Marginal zone lymphoma Cytomegalovirus infection Congenital myopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rue Frederic Combemale, Lille, 59000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Carboplatin
    • Cemiplimab
    • Paclitaxel
    France

  • Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Sorafenib
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Germany Ireland +4

  • Study on Cabozantinib and Nivolumab for Older Patients with Kidney Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabozantinib
    • Nivolumab
    France

  • Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

    Recruiting

    2 1 1
    Investigated Drugs:
    • 3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE
    • Bay 2927088
    • SEVABERTINIB
    Denmark France Italy Spain

  • Study Comparing Serratus Plane Block, Capsaicin, and Botulinum Toxin Type A for Chronic Pain in Post-Mastectomy Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Post breast therapy pain syndrome
    • Neuralgia
    Investigated Drugs:
    • Dobutamine Hydrochloride
    • MORPHINE
    • Oxycodone Hydrochloride Ph. Eur.
    France

  • Study Comparing Ivonescimab to FOLFOX Drug Combination for Patients with Advanced Biliary Tract Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Calcium Levofolinate
    • Ivonescimab
    • Calcium Folinate
    France

  • Study of cobimetinib and atezolizumab combination therapy in children and adults with advanced or metastatic soft tissue sarcoma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Soft tissue sarcoma
    Investigated Drugs:
    • Cobimetinib
    • Atezolizumab
    France

  • Study of Ezabenlimab and Drug Combination for Stage III Anal Cancer Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Anal squamous cell carcinoma
    Investigated Drugs:
    • Ezabenlimab
    • Mitomycin
    • Capecitabine
    France

  • Study on the Effectiveness of Imatinib for Patients with Intermediate-Risk Gastrointestinal Stromal Tumor and High Genomic Grade Index

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastrointestinal stromal tumour
    Investigated Drugs:
    • Imatinib Mesilate
    France

  • Study on Post-Operative Chemotherapy with Doxorubicin and Trabectedin for Patients with High-Risk Localized Uterine Leiomyosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Uterine leiomyosarcoma
    Investigated Drugs:
    • Trabectedin
    • Doxorubicin Hydrochloride
    France Spain
Previous Page
1 … 3 4 5 6 7 … 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!